Molika Ashford

Research presented at the ASCO meeting described efforts to expand the use of existing technologies into new directions.

The company presented its first analyses answering crucial questions about real-world performance and impact on patients' well-being and healthcare utilization.

The company plans to recruit about 12,000 individuals, split between cancer cases and controls, to train and test a newly developed 22-cancer early detection test.

The new reports link variants in CYP2C19 to the safety and efficacy of two drugs, a commonly prescribed antiplatelet drug and an antidepressant.

The company expects to launch testing for advanced cancer patients this year, with studies now running to expand to cancer screening and monitoring applications.

The firm also hopes to use its metatranscriptomics approach to develop diagnostics and therapeutics for a variety of other disease areas.

The data, while limited, indicate that the firm's blood-only assay may be able to match the performance of existing commercial tissue-informed competitors.

The firm is expanding its plans from a Crohn's disease test to a broader GI differential diagnostic and continues to expect to launch its Lyme disease assay by year-end.

The firm continues to pursue new applications for its multiomics machine learning technology, with recent data exploring immunotherapy response prediction.

Recent results from the firm's case-control study cohort showed overall sensitivity of about 50 percent but higher performance for a subset of high-mortality cancers.